ADISCTI (AdisInsight Trials, formerly Adis Clinical Trials Insight)
Subject
Coverage

AdisInsight Trials (file label: ADISCTI) contains profiles of pharmaceutical clinical trials
and the results published from these trials. Profiles are written by Adis experts andupdated weekly with the latest information posted on clinical trial registries, published in
global literature, and presented in conference abstracts from around the world.
Highlights of the records include study progress, subject enrollment, study centers,
investigators, and clinical results for efficacy and safety.

File Type

Bibliographic, Full text

Features

Alerts (SDIs)

WeeklyCAS Registry
Number® IdentifiersKeep & Share

Learning Database

Page Images
SLART




RecordContent• Bibliographic and indexing information• Profiles contain disease studied, drug dosage information, subject inclusion/exclusion
criteria, study progress, study endpoints, reported efficacy and safety.

File SizeMore than 211,000 records (01/22)

Coverage

1998-present

Updates

WeeklyLanguage

English

Database
Producer

Springer Nature Switzerland AG
Copyright Holder
Contact Springer Online Services support desk:
Email: onlineservice@springer.com
Phone: +49 6221 345 4303 (Europe/Asia/Africa)+1 800 777 4643 (North & South America)

January 2022

2
ADISCTI

Sources

•
•
•
•
•
•
•

User Aids• Online Helps (HELP DIRECTORY lists all help messages available)• STNGUIDE

Clusters• ADISBASES• ALLBIB• AUTHORS• BIOSCIENCE• CORPSOURCE• FULLTEXT• HEALTH• MEDICINE• PHARMACOLOGY• TOXICOLOGYSTN Database Clusters information (PDF).

January 2022

Direct contact with companies involved with research and development
Major clinical trial registries including clinicaltrials.gov, eudraCT, and WHO
1,700 biomedical and medical journals
International meetings and conferences
Company annual reports
News services
Press releases

3
ADISCTI

Search and Display Field Codes
Fields that allow left truncation are indicated by an asterisk (*).

General Search Fields
Search Field Name

SearchCode

Display
Codes

Search Examples

Basic Index * (contains single words
from the title (TI), controlled term (CT),text (TX), andevaluation (EVAL) fields)None(or /BI)S PHARMACOKINETICSS QUALITY OF LIFES RESIST? (L) NEGATIVES VACCINE# (S) USE
S PATIENT-CONTROLLEDS ?DIABET(L)?THERAP?

CT, EVAL,
TI, TX

Accession Number
ADIS Last Update Date (2)ADIS Record Creation Date (2)Author

/AN
/DUP
/DED
/AU

AN
DUP
DED
AU

Controlled Term

/CT

Controlled Word

/CW

Corporate Source (organization nameand location) (1)Document Number
Document Type (text)/CS

S 2006:1005/AN
S 20051004/DUP
S 20051004/DED
S JENSEN P?/AU
S JENSEN, P?/AU
S THERAPEUTIC EQUIVALENCE/CT
S CORONARY SPASM, TREATMENT/CT
S (ACICLOVIR (L) ACTIVITY)/CWS (INHIBITORS (S) ANTIMICROBIAL)/CW
S (VETERANS AFFAIRS AND
ALABAMA)/CS
S 801032402/DN
S BEST EVIDENCE/DT
S L1 AND ED>=20051100
S CONTROLS/EVALS MEDIA RELEASE/EVAL
S L3 AND SIDE/FA
S 8750-2836/ISN

ED
EVAL

S REGION ANESTH/JTS REGIONAL ANESTHESIA/JT
S L2 AND ENGLISH/LA
S L2 AND EN/LAS PNO<=100
S TRANSDERMAL?/OT
S 2006000118/OS
S ADISINSIGHT/OSS JUN 1-30 2005/PD
S 2004/PY
S EPILEPSY DISORDERS/RE
S (BIOLO? AND BULL? AND VOL 20)/SO

JT, JTA,
JTF, SOLAS (VITRO AND ACTIVITY)/TI
S ?MALARIA?/TI
S (KETOLIDE (S) ANTIMICROBIAL)/TI
S L7 AND 20021100-20021200/UP
S L1 AND WC<200

TI

Entry Date (2)Evaluation (3,4)/DN/DT(or /TC)/ED/EVAL

Field Availability
International Standard (Document)
Number
Journal Title (contains full andabbreviated journal titles)
Language (code and text)

/FA
/ISN

Number of Patients (2,3)
Ongoing Trial Comment
Other Source

/PNO
/OT
/OS

Publication Date (2)Publication Year (2)Reference (1)Source (contains journal title,
publication date, ISSN, and collation
information (volume, issue, and page
numbers))
Title *

/PD
/PY
/RE
/SO

Update Date (2)Word Count (2,3)

/UP
/WC

/JT
/LA

/TI

CT
CT
CS
DN
DT

Not displayed
ISN, SO

PNO
OTOS
PD, SOPY, SO
RE
SO

ED
WC

January 2022

4
ADISCTI(1) Implied (S) proximity is available in this field.
(2) Numeric search field that may be searched using numeric operators or ranges.
(3) This field is available only in the SUMMARY file segment.
(4) See HELP SCORE for more information.
(5) This score is only available in selected records published in November 2010 and earlier.

DISPLAY and PRINT Formats
Any combination of formats may be used to display or print answers. Multiple codes must be separated by
spaces or commas, e.g., D L1 1-5 TI AU. The fields are displayed or printed in the order requested.
Hit-term highlighting is available for all fields. Highlighting must be ON during SEARCH to use the HIT, KWIC,
and OCC formats.
FormatAN (1)AUCS
CT (1)DED
DN
DT (TC)DUP
ED
EVAL (2)ISN
JT (3)JTA (3)
JTF (3)LAOS
OT
PD (3)PNO (1,2)
PY (3)RE
SO
TI (1)TX (2)UP
WC (1,2)
ALL
BIB
CBIB

January 2022

Content

ExamplesAccession Number
AuthorCorporate Source
Controlled Term (Drug Descriptors, Disease Descriptors, and Other
Descriptors)
ADIS Record Creation Date
Document Number
Document TypeADIS Last Update Date
Entry Date
Evaluation (Positive Features, Negative Features, Adis Comment, andAdis Evaluation)
International Standard (Document) Number
Journal Title, Full and Abbreviated
Journal Title, Abbreviated
Journal Title, Full
Language
Other Source
Ongoing Trial Comment
Publication Date
Number of Patients
Publication Year
Reference
SourceTitle
Text (Global Study Outcome (Efficacy, Tolerability, Pharmacoeconomics),
Study Message (Efficacy, Tolerability), Results Highlights (Efficacy,
Tolerability), Purpose, Author Comments, Study Details (Design, Control,
Phase, Methodology, EndPoints, Companies) Subject Details (Type, No.,
Age, Sex, Location, Disease, Characteristics), Drug, Drug Table(Drug/Treatment, Dose, Route, Frequency, Duration), Results (Results
Table), Case Details (Toxicity, Dechallenge, Outcome, Claimed Association,
Key Details), and Age Key)
Update Date
Word CountD L4 1-4 AN
D AU CSD CS 1,3-5
D CT 5-10

AN, DN, TI, AU, CS, SO, DT, DED, DUP, RE, LA, WC, OS, ED, EVAL, TX,
PNO, CTAN, DN, TI, AU, CS, SO, DT, DED, DUP, RE, LA, WC, OS, ED
BIB in compressed format

D ALL

D DED
D 1-3,7,8 DN
D DT
D DUP
D ED
D EVAL 1 5
D ISN
D JT
D JTA 2
D JTf
D LA
D OS
OT
D PD
D PNO
D PY
D RE
D SO
D TI
D TX

D UP
D WC

D 2 L5 BIB
D CBIB

5
ADISCTIDISPLAY and PRINT Formats (cont'd)FormatContent

Examples

DALL
IALL
IBIB
IND (1)
SCAN (1,4)
TEXT (2)TRIAL(TRI, SAM) (1)ALL, delimited for post processing
ALL, indented with text labels
BIB, indented with text labels
PNO, CT
TI, PNO, CT (random display, no answer numbers)
EVAL, TX, PNO
TI, PNO, CT

D DALLD IALLD IBIBD IND
D SCAND TEXT
D TRIAL TOTAL

HIT
KWIC
OCC (1)

Fields containing hit terms
Hit terms with 20 words on either side (KeyWord-In-Context)
Number of occurrences of hit terms and fields in which they occur

D HIT
D KWIC NOH
D OCC(1) No online display fee for this format.
(2) This field is available only in the SUMMARY file segment.
(3) Custom display format only.
(4) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.

SELECT, ANALYZE, and SORT Fields
The SELECT command is used to create E-numbers containing terms taken from the specified field in ananswer set.
The ANALYZE command is used to create an L-number containing terms taken from the specified field in ananswer set.
The SORT command is used to rearrange the search results in either alphabetic or numeric order of thespecified field(s).

Field Name
Accession Number
ADIS Last Record Update
ADIS Record Creation Date
AuthorCitationControlled Term
Corporate Source
Document Number
Document Type
Entry date
Evaluation (4)File Segment
International Standard (Document) Number
Journal Title
Journal Title, Abbreviated
Journal Title, Full
Language
Number of Patients (4)Occurrence Count of Hit Terms
Ongoing Trial Comment
Other Source

Field Code
AN
DUP
DED
AU
CIT
CT
CS
DN
DT
ED
EVAL
FS
ISN
JT
JTA
JTF
LA
PNO
OCC
OT
OS

ANALYZE/
SELECT (1)Y
YYY
Y (2,3)
Y
Y
Y
Y
Y
Y
Y
Y
Y (5)
Y (6)
Y (6)
Y
Y
N
Y
Y

SORT
N
Y
Y
Y
N
N
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
N
N

January 2022

6
ADISCTI

SELECT, ANALYZE, and SORT Fields (cont'd)
Field Name

Field CodePublication Date
Publication Year
Reference
Text (4)
Title
Treatment CodeUpdate Date
Word Count (4)

PD
PY
RE
TX
TI
TC
UP
WC

ANALYZE/
SELECT (1)

SORT

Y
Y
Y
Y (7)
Y (default)
Y
Y
N

Y
Y
Y
N
Y
Y
Y
Y

(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HITCT.
(2) SELECT HIT and ANALYZE HIT are not valid with this field.
(3) Extracts first author, publication year, volume, and first page with a truncation symbol appended and with /RE appended to the terms
created by SELECT.
(4) This field is available only in the SUMMARY file segment.
(5) Selects or analyzes full and abbreviated journal titles with /JT appended to the terms created by SELECT.
(6) Appends /JT to the terms created by SELECT.
(7) Appends /BI to the terms created by SELECT.

Full-Text Browsing
User Request

ExampleSystem Response

DISPLAY BROWSE=> DISPLAY BROWSEENTER (L1) OR L#:.
ENTER (DIS), ANSWERNUMBERS, OR END:

NOVICE version

D BRO

EXPERT version

Answer number(s)=> D BRO L1::1-3

Answer number(s) and format
Format only

:4 HIT:TI TX

Change default format:*KWIC

Forward n fields
Backward n fields
Search forward forcharacter string
Search backward forcharacter string
End DISPLAY BROWSE:F3:B1:S BONE MARROW

January 2022

:S- NAUSEA:END=>

display answers 1, 2, and 3 indefault format
display answer 4 in HIT format
display title and text of last answer
displayedchange default to KWIC
no answer displayed
move forward 3 fields
move backward 1 fieldsearch forward within recordfor ‘bone marrow’search backward within recordfor ‘nausea’exit DISPLAY BROWSE and returnto => prompt

7
ADISCTI

Sample Records
DISPLAY IALLACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:
DOCUMENT TYPE:ADIS REC. CREATED:ADIS LAST UPDATE:REFERENCE:LANGUAGE:
WORD COUNT:OTHER SOURCE:
ENTRY DATE:ONGOING TRIAL COMNT:

2006:18471
ADISCTI
700009023
ADIS TITLE: Effectiveness of an NK1 Antagonist in
PTSD.
Ongoing Trial
26 Nov 2005
4 Mar 2014
Anxiety Disorders; Mental Disorders
1.) ClinicalTrials.gov: US National Institutes of
HealthEnglish283
ADISINSIGHT 1998005744
Entered STN: 12 Jun 2006
Last Updated on STN: 7 Mar 2014
Ongoing Trial Comment: This trial is entitled"Effectiveness of an NK1 Antagonist [vofopitant] in
PTSD [post-traumatic stress disorder]". The primary
outcome is the change in 17-item total severity
Clinician Administered PTSD Scale.

TEXT - Subject Details:
Planned No: 47
No: 64
Location: USA
Disease: Post-traumatic-stress-disorders
Patient Inclusion: Aged 18-65 years; diagnosis of post-traumatic stressdisorder for greater than or equal to 3 months; negative urine toxicology
test; females willing to use an effective form of birth control throughout the
study.
Patient Exclusion: Current diagnosis of schizophrenia or other psychotic
disorder, current diagnosis of bipolar disorder or other psychiatric disorder
except for depression secondary to post-traumatic stress disorder,
participation in a clinical trial of a new drug during the previous 4 months
or any other trial during the previous 3 months, current evidence or historyof serious unstable medical illness or organic brain impairment, serious
suicidal or homicidal risk, substance abuse within the last 90 days, use ofeffective psychiatric medications in the 2 weeks prior to screening or***fluoxetine***in last 5 weeks, consumption of more than 4 drinks/day per
week if male or of more than 3 drinks/day per week if female, donation ofblood within the previous month or intent to donate blood within one month ofcompleting the study, previous treatment with an NK1 antagonist.
TEXT - Age Key: adult, elderly
TEXT - Study Details:
Status: completed
Actual Start: August 2005
Planned Finish: November 2008
Actual Finish: November 2008
Design: double-blind, parallel, prospective, randomised
Phase: II
Endpoints: Assessment scale scores
Biomarker levels (CSF levels of norepinephrine (NE) and NE metabolites.)
Brain volume (Hippocampal volume.)
clinical Global Impressions scale
Clinical response rate
Improvement in symptoms
Magnetic resonance imaging outcomes, Clinician Administered Post-TraumaticStress Disorder Scale
Study Center: Baylor School of Medicine, Mount Sinai School of Medicine, Emory
University, National Institute of Mental HealthCompanies: GlaxoSmithKline

January 2022

8
ADISCTI
ID: 700009023 (Clinical Trials Insight)
NCT00211861 (ClinicalTrials.gov: US National Institutes of Health)
U19MH069056()
NO. OF PATIENTS:

64

CONTROLLED TERM:CONTROLLED TERM:

Drug Descriptors: VofopitantDisease Descriptors: Post traumatic stress disorders,treatment

In North America
CAS
STN North America
P.O. Box 3012
Columbus, Ohio 43210-0012 U.S.A.
CAS Customer Center:Phone: 800-753-4227 (North America)
614-447-3700 (worldwide)Fax:
614-447-3751
Email:
help@cas.org
Internet: www.cas.org

January 2022

In Europe
FIZ Karlsruhe
STN Europe
P.O. Box 2465
76012 Karlsruhe
Germany
Phone: +49-7247-808-555
Fax:+49-7247-808-259
Email:
helpdesk@fiz-karlsruhe.de
Internet: www.stn-international.com

In Japan
JAICI (Japan Association forInternational Chemical Information)
STN Japan
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021, Japan
Phone: +81-3-5978-3601 (Technical Service)+81-3-5978-3621 (Customer Service)
Fax:+81-3-5978-3600
Email:
support@jaici.or.jp (Technical Service)customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp